Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 2,357 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 2,357 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $35.06, for a total transaction of $82,636.42. Following the completion of the transaction, the director now owns 190,939 shares of the company’s stock, valued at approximately $6,694,321.34. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dirk Kersten also recently made the following trade(s):

• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.32, for a total transaction of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Trading Down 2.3 %

NASDAQ DYN opened at $33.83 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of -8.52 and a beta of 1.07. The company has a fifty day simple moving average of $40.26 and a 200 day simple moving average of $33.93. Dyne Therapeutics, Inc. has a 12-month low of $6.40 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Sell-side analysts predict that Dyne Therapeutics, Inc. will post -2.96 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Morgan Stanley raised their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. raised their price target on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Stifel Nicolaus raised their price target on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Piper Sandler restated an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently bought and sold shares of DYN. RA Capital Management L.P. purchased a new position in Dyne Therapeutics during the 1st quarter worth $140,666,000. Janus Henderson Group PLC raised its stake in shares of Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock worth $75,915,000 after purchasing an additional 2,663,910 shares during the period. Frazier Life Sciences Management L.P. bought a new stake in shares of Dyne Therapeutics during the 4th quarter worth $15,758,000. Price T Rowe Associates Inc. MD raised its stake in shares of Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after purchasing an additional 1,110,629 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.